The Medicines Company (MDCO): Today's Featured Drugs Laggard

Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link.

Medicines Company ( MDCO) pushed the Drugs industry lower today making it today's featured Drugs laggard. The industry as a whole closed the day up 1.2%. By the end of trading, Medicines Company fell $4.40 (-15.5%) to $24.02 on heavy volume. Throughout the day, 8,956,202 shares of Medicines Company exchanged hands as compared to its average daily volume of 971,600 shares. The stock ranged in price between $23.53-$24.69 after having opened the day at $23.89 as compared to the previous trading day's close of $28.42. Other companies within the Drugs industry that declined today were: Prana Biotechnology ( PRAN), down 17.9%, Bio-Path Holdings ( BPTH), down 14.7%, Reliv' International ( RELV), down 11.4% and Galectin Therapeutics ( GALT), down 11.3%.

The Medicines Company provides medical solutions for patients in acute and intensive care hospitals worldwide. Medicines Company has a market cap of $1.8 billion and is part of the health care sector. Shares are down 26.4% year to date as of the close of trading on Monday. Currently there are 5 analysts that rate Medicines Company a buy, no analysts rate it a sell, and 2 rate it a hold.

TheStreet Ratings rates Medicines Company as a hold. The company's strengths can be seen in multiple areas, such as its robust revenue growth, largely solid financial position with reasonable debt levels by most measures and good cash flow from operations. However, as a counter to these strengths, we also find weaknesses including a generally disappointing performance in the stock itself, feeble growth in the company's earnings per share and deteriorating net income.

On the positive front, Amyris ( AMRS), up 19.0%, Arrowhead Research Corporation ( ARWR), up 11.3%, Tonix Pharmaceuticals ( TNXP), up 11.1% and Genvec ( GNVC), up 10.6% , were all gainers within the drugs industry with Gilead ( GILD) being today's featured drugs industry leader.

For investors not wanting singular stock exposure, ETFs may be of interest. Investors who are bullish on the drugs industry could consider SPDR S&P Pharmaceuticals ETF ( XPH) while those bearish on the drugs industry could consider ProShares UltraShort Nasdaq Biotech ( BIS).

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. Learn more.

More from Markets

Flashback Friday: the Market Movers

Flashback Friday: the Market Movers

OPEC Deal Doesn't Boost Production Enough to Drive Down Crude, Gasoline Prices

OPEC Deal Doesn't Boost Production Enough to Drive Down Crude, Gasoline Prices

Dow Posts First Gain in Nine Sessions; Oil Jumps

Dow Posts First Gain in Nine Sessions; Oil Jumps

Amazon's Big Weakness in the Supreme Court Sales Tax Ruling

Amazon's Big Weakness in the Supreme Court Sales Tax Ruling

3 Must Reads on the Market From TheStreet's Top Columnists

3 Must Reads on the Market From TheStreet's Top Columnists